What is Factor VIII related antigen (Factor VIII related antigen) a marker of?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Factor VIII Related Antigen as a Marker for Vascular Tumors

Factor VIII related antigen is a marker of Kaposi's sarcoma, making option A the correct answer. This protein serves as an endothelial cell marker that has been consistently demonstrated in the cells of Kaposi's sarcoma through immunohistochemical studies.

Evidence Supporting Kaposi's Sarcoma Origin

  • Immunohistochemical studies have consistently demonstrated Factor VIII related antigen (FVIIIRA) in the cells of Kaposi's sarcoma, providing strong evidence for its endothelial cell origin 1.
  • Positive reactions for Factor VIII related antigen have been noted in all cases of Kaposi's sarcoma regardless of their histologic variations, with staining present in both cells lining vascular channels and in the intertwining spindle cells 1.
  • Multiple studies have shown that the spindle cell component of Kaposi's sarcoma stains positively for Factor VIII related antigen in the majority of cases (6 out of 7 cases in one study) 2.

Diagnostic Value in Vascular Tumors

  • Factor VIII related antigen is considered a specific marker for vascular tumors, with positive staining observed in angiomas and angiosarcomas, while showing negative staining in carcinomas 2.
  • In non-vascular sarcomas, false positive results for Factor VIII related antigen are rare (only 2.2% in one study), further confirming its specificity for vascular tumors 2.
  • The presence of Factor VIII related antigen in Kaposi's sarcoma cells strongly supports an endothelial derivation since this marker is elaborated only by endothelial cells and megakaryocytes 1.

Comparison with Other Vascular Markers

  • While CD34 and CD31 may be more reliable for labeling Kaposi's sarcoma than Factor VIII related antigen in some studies, Factor VIII remains a traditional endothelial cell marker used in the diagnosis 3.
  • Factor VIII related antigen has been shown to label well-formed capillaries in vascular tumors, though it may be less consistent in labeling spindle cells compared to CD34 3.
  • The specificity of Factor VIII related antigen for blood vessel endothelium has been debated, but its presence in Kaposi's sarcoma has been consistently demonstrated across multiple studies 4.

Technical Considerations

  • The interpretation of positive peroxidase labeling for Factor VIII related antigen is important, with positive labeling of tumor spindle cells accepted only when it matches that seen in labeled endothelial cells 5.
  • Variations in techniques, immunoreagents, and fixation methods may affect the detection of Factor VIII related antigen in tissue samples 5.
  • Polyclonal antibodies have been reported to provide more satisfactory localization of Factor VIII related antigen compared to monoclonal antibodies in some studies 5.

Differential Diagnosis

  • Factor VIII related antigen helps distinguish Kaposi's sarcoma from other spindle cell tumors of the skin, as it is consistently present in Kaposi's sarcoma but absent in most non-vascular tumors 1.
  • While melanoma (option B), post-mastectomy angiosarcoma (option C), desmoid tumors (option D), and Merkel cell carcinoma (option E) may be in the differential diagnosis of spindle cell lesions, Factor VIII related antigen is specifically associated with vascular tumors like Kaposi's sarcoma 2, 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.